The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance

Helicobacter

Volumn 7, Issue 5, 2002, Pages 306-309

  Perez Aldana, L ^a   Kato, M ^a   Nakagawa, S ^a   Kawarasaki, M ^a   Nagasako, T ^a   Mizushima, T ^a   Oda, H ^a   Kodaira, J ^a   Shimizu, Y ^a   Komatsu, Y ^a   Zheng, R ^a   Takeda, H ^a   Sugiyama, T ^a   Asaka, M ^a   Mototsugu, Kato ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Antibiotic consumption; Clarithromycin; Helicobacter pylori; Metronidazole; Resistance

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG USE; ERADICATION THERAPY; FEMALE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 18644378213     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5378.2002.00096.x     Document Type: Article

References (22)

1. NIH Consensus Conference. NIH Consensus Development panel on Helicobacter pylori in peptic ulcer disease: Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
2. American Digestive Health Foundation. The report of the digestive health initiative international update conference on Helicobacter pylori. Gastroenterology 1997;113:S4-S8.
3. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345:784-9.
4. Kato M, Yamaoka Y, Kim JJ, et al. Regional difference in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000;44:2214-6.
5. Murakami K, Kimoto M. Antibiotic-resistance. H. pylori strains in the last ten years in Japan. Nippon Rinsho 1999;57:81-6.
6. Megraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998;54:207-15.
7. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997;11:43-53.
8. Mendoca S, Ecclissato C, Sartori MS, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and furazolidone in Brazil. Helicobacter 2000;5:79-83.
9. Dore MP, Piana A, Carta M, et al. Amoxycillin resistance is one reason for the failure of amoxicillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:635-49.
10. Graham DY. Antibiotic resistance in Helicobacter pylori: Implication for therapy. Gastroenterology 1998;115:1272-7.
11. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999;12:341-7.
12. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161:1217-20.
13. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-99. Ann Intern Med 2002;136:13-24.
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; ninth informational (Suppl.) Pennsylvania, USA. NCCLS, 1999:M100-S9.
15. Xia H, Keane CT, Beattle S, O'Morain CA. Standardization of disk difussion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 1994;38:2357-61.
16. Miyaji H, Azuma T, Ito S, et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxicillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997;11:1131-6.
17. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin influence to treatment outcome. Am J Gastroenterol 1998;93:386-9.
18. Xia H, Buckley M, Keane CT, O'Morain CA. Clarithromycin resistance in Helicobacter pylori: Prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996;37:473-81.
19. Schutze K, Hentschel E, Hirshl AM. Clarithromycin or amoxicillin plus high-dose ranitidine in the treatment of Helicobacter pylori-positive functional dyspepsia. Eur J Gastroenterol Hepatol 1996;8:41-6.
20. Megraud F. Resistance of Helicobacter pylori to antibiotics: The main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999;11:S35-7.
21. Utrup LJ, Tanaka SK, Olson CA, Graham DY. Clarithromycin susceptibility testing breakpoints for H. pylori (Abstract). Gut 1996;39:A11-2.
22. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: When does choosing the treatment regimen based on susceptibility testing become cost-effective? Am J Gastroenterol 1999;94:725-9.